

Laurie H. Glimcher, MD
Marion Spencer Fay Award Honoree - 2016



Laurie H. Glimcher, MD, is the incoming president and chief executive officer of the Dana Farber Cancer Institute, and professor of medicine at Harvard Medical School. She is the former Stephen and Suzanne Weiss Dean and Professor of Medicine of Weill Cornell Medical College in New York City, and provost for medical affairs of Cornell University. Previously, she was the Irene Heinz Given Professor of Immunology at the Harvard School of Public Health, where she was director of the Division of Biological Sciences, and professor of medicine at Harvard Medical School, where she headed one of the top immunology programs in the world. She also served as senior physician and rheumatologist at the Brigham and Women's Hospital.

Dr. Glimcher received her postdoctoral training at Harvard and in the Laboratory of Immunology at the National Institute of Allergy and Infectious Diseases in Bethesda, Maryland, and is board certified in internal medicine and rheumatology. She received her BA degree from Radcliffe College and her MD from Harvard Medical School. As an immunologist, her primary research interests are the biochemical and genetic approaches that elucidate the molecular pathways that regulate CD4 T helper cell development and activation. The complex regulatory pathways governing T helper cell responses are critical for both the development of protective immunity and for the pathophysiologic immune responses underlying autoimmune, infectious and malignant diseases. Dr. Glimcher's research laboratory has studied the transcriptional pathways that control this important immune checkpoint, leading to many discoveries, including the c-Maf and T-bet transcription factors, which regulate a variety of adaptive and innate immune functions. She also discovered XBP1, the first transcription factor required for plasma cell differentiation and the endoplasmic reticulum (ER) stress response. She demonstrated a link between ER stress and proinflammatory/autoimmune diseases in intestinal epithelial cells and in macrophages. Most recently she has discovered a key role for XBP1 in both tumor cells and in host immune responses. In addition, her laboratory has identified new proteins that control osteoblast and osteoclast commitment and activation in skeletal biology with significant implications for diseases of bone, including osteoporosis, rheumatoid arthritis, osteoarthritis and cancer metastasis to bone.

Dr. Glimcher is the recipient of numerous awards and honors, including the Soma Weiss Award for Undergraduate Research, the Distinguished Young Investigator Award from

the American College of Rheumatology, the Leukemia Society's Stohlman Memorial Scholar Award, the Arthritis Foundation's Lee S. Howley Award, the FASEB Excellence in Science Award, the American Society of Clinical Investigation Investigator Award, the Klemperer Award, the AAUW Senior Scholar Award, the Huang Meritorious Career Award, the AAI Excellence in Mentoring Award, the Dean's Award for Leadership in the Advancement of Women Faculty, and the American College of Rheumatology Distinguished Investigator Award. In 2012 she received the Ernst W. Bertner Memorial Award (MD Anderson Cancer Center), the Cancer Research Institute William B. Coley Award, and the Luis Federico Leloir Prize to International Cooperation in Science, Technology and Innovation, Ministry of Health, Argentina. In 2014 she received the Vanderbilt Prize, the L'Oreal:UNESCO Award, the Margaret Kripke Legend Award and in 2015 the Steven Beering Award. She is the 2017 recipient of the Kober Medal Award from the American Association of Physicians.

She is a fellow of the American Academy of Arts and Sciences, a member of the Institute of Medicine of the National Academy of Sciences and a member of the National Academy of Sciences. She is the former president of the American Association of Immunologists. She is a member of the American Asthma Foundation and Cancer Research Institute Scientific Advisory Boards and served on the Burroughs-Wellcome Fund and HHMI Scientific Advisory Boards. She sits on the board of trustees of Memorial Sloan Kettering Cancer Center and is on the corporate board of directors of the Bristol-Myers Squibb Pharmaceutical Corporation and the Waters Corporation.

Dr. Glimcher speaks nationally and internationally on rheumatology, cancer, immunology, skeletal biology and translational medicine and has contributed more than 350 scholarly articles and papers to the medical literature.